Plasma Copeptin in Response to Oral Urea in Healthy Adults and Patients With Polyuria-polydipsia Syndrome — URANOS  

Primary Polydipsia Clinical Trial

Official title: Plasma Copeptin in Response to Oral Urea in Healthy Adults and Patients With Polyuria-polydipsia Syndrome: a Double-blind, Randomized, Placebo-controlled Cross-over Proof-of-concept and Pilot Study - The URANOS Study

Status Recruiting

Clinical Trial Summary

The aim of this study is to investigate whether oral urea stimulates copeptin release and, if so, whether it may provide a novel diagnostic test in the differentiation between AVP-D (Arginine vasopressin deficiency) and PP (primary polydipsia).

Clinical Trial Description

This study consists of two parts, including healthy adults (study part 1 - proof of concept) and adults with an established diagnosis of PP or AVP-D (study part 2 - pilot study). If the results of study part 1 suggest that oral urea is a potent stimulator of copeptin in healthy adults, study part 2 will be conducted, meaning that adults with an established diagnosis of PP or AVP-D will be included. If study part 1 demonstrates no relevant copeptin increase in response to oral urea, the study will be terminated thereafter and study part 2 will not be conducted. ;

Related Conditions & MeSH terms

• Diabetes Insipidus
• Polydipsia
• Polyuria
• Primary Polydipsia

• NCT number: NCT05890690
• Study type: Interventional
• Source: University Hospital, Basel, Switzerland
• Contact: Mirjam Christ-Crain, Prof.
• Phone: +41 61 328 70 80
• Email: mirjam.christ-crain@usb.ch
• Status: Recruiting
• Phase: N/A
• Start date: June 2, 2023
• Completion date: December 2024